Brookfield Asset Management BAM

Reference table

1. What the business actually is — and what this dataset can and cannot tell us

Brookfield Asset Management Ltd. (NYSE: BAM, incorporated in Canada, headquartered at Brookfield Place, New York; CEO Connor David Teskey; 5,800 full-time employees; IPO'd in its current listed form on 2022-12-01) is the pure-play asset-management arm of the Brookfield group. Per the company profile in this dataset it "operates as a prominent alternative asset manager… specializing in real estate, renewable energy, infrastructure, venture capital, and private equity assets," providing "public and private investment products and services to institutional and retail clients globally."

The reported segment split for FY25 (2025-12-31) is unusually simple:

Data caveat, stated up front: those two segments sum to $3.944B, while the FY25 income statement reports $4.608B of revenue. The $664M gap is not explained in this dataset — it may be fee-related items not allocated to the two named lines. Treat the 85.8/14.2 split as a mix signal, not a full revenue bridge.

Second data caveat, more important. The geographic disclosure for FY25 lists United States $27.356B, Canada $7.808B, Other Europe $7.022B, Brazil $5.483B, Australia $5.314B, India $4.245B, Other Countries $3.143B, Other Asia $2.744B, Colombia $2.679B and Germany $2.322B — a total of $68.116B, roughly fifteen times the reported $4.608B of income-statement revenue. These are plainly group-level figures (assets or gross revenues across the managed Brookfield complex), not BAM Ltd.'s own revenue. They should be read as a footprint map only — evidence of genuinely global reach with the United States at ~40% of it — and must not be used in any per-share arithmetic. This dive does not use them for anything else.

Third data caveat, and the one that governs the whole financial history. BAM's reported share count and balance sheet are discontinuous across the 2024-25 corporate reorganisation:

A share count that goes 389M → 1,121M → 1,646M and total assets that quadruple in one year are not organic. Pre-2025 per-share history is not comparable and is not used in this dive. Every growth rate quoted below is either FY24→FY25 (post-restructuring), quarter-over-year-ago-quarter, or forward consensus.

2. The earnings engine — why the margins are what they are

Strip away the structure and BAM is a very clean set of numbers.

FY25 (2025-12-31) versus FY24:

Q1'26 (2026-03-31) versus Q1'25:

Note the divergence in Q1'26: revenue accelerated to +22.1% while operating income fell 21.2%, because reported operating expenses jumped from $6M (Q1'25) to $443M (Q1'26). Net income still rose, helped by a lower tax charge ($108M versus $75M on a much larger pretax base) and non-operating items. Read this as one noisy quarter in a restructured entity, not as margin deterioration — but it is the reason the operating-margin series is not quoted as a trend here.

The TTM profitability profile is the real evidence:

• Gross margin 71.8% · EBITDA margin 66.0% · operating margin 63.1% · net margin 52.3%
• Return on equity 30.0% · return on invested capital 53.1% · return on capital employed 18.2%
• SG&A just 1.5% of revenue · R&D zero · stock-based comp 7.4% of revenue
• Interest coverage 18.8x · net-debt/EBITDA 1.39x · current ratio 1.42x

A business converting more than half of revenue to net income, on a 53% return on invested capital, with 1.4 turns of leverage, is a genuinely superior structure. That is not in dispute anywhere in this dive.

3. The knowledge base — this ticker has NO coverage, and the adjacent lane is negative

This is the section that most distinguishes a Synthos dive, and here it delivers an uncomfortable answer.

Direct coverage: zero. A sweep of the full tracked corpus for the symbol BAM and for "Brookfield" returns no claim that names this ticker. For completeness, here is everything that touches the Brookfield franchise at all:

Verdict on coverage: kb_claim_count 0, breadth 0. No tracked thinker underwrites this ticker. Per the STM and NVTS precedent, that is an accepted outcome and not a reason to manufacture conviction. It does, however, cap position size: a name nobody on the panel owns does not earn a core weight.

The adjacent lane, and why it is not neutral. What the knowledge base does carry, in volume and recently, is a bearish read on the asset class BAM sells into. A sweep for private credit and alternative-manager claims returns 230 entries, with the July-August 2026 cluster running distinctly negative:

• eurodollar_university, 2026-07-04 (bearish, conviction 80): "Private credit has entered a defensive 'regime change' phase — repeat massive redemptions, capped withdrawals, ~$14B trapped, leadership changes and losses — no longer a nothing-burger."
• eurodollar_university, 2026-07-08 (bearish, 78): "Private credit cycle is turning: HSBC, JPMorgan, Goldman, Barclays are pulling back leverage, refusing renewals and marking down collateral — insiders de-risking signals downside confirmed."
• eurodollar_university, 2026-08-01 (bearish, 76): "The credit downturn is not contained to private credit; public markets are now doing price discovery and finding cracks across the entire credit edifice."
• eurodollar_university, 2026-08-01 (bearish, 68): entities ['ARCC','OWL'] — "BDC stocks (Blue Owl, Ares, Goldman) keep hitting new lows for over a year; the market demands a margin of safety the private portfolio marks aren't showing."
• odd_lots, 2026-07-31 (bearish, 65): "Private credit assets on insurer balance sheets are systematically overvalued; new empirical papers 'continually find overvaluation,' enabled by opaque private-letter ratings the NAIC can't independently verify."
• odd_lots, 2026-08-02 (neutral, 65): "Roughly $750 billion of life-insurance assets are now within private equity's purview, and PE is shifting insurers' portfolios from stodgy AAA bonds toward affiliated private credit."

How much should this weigh on BAM specifically? Less than it would on a credit-heavy manager, and this dive says so plainly. Brookfield's franchise is tilted to real assets — infrastructure, renewables, real estate — not to the direct-lending and BDC structures those claims describe. Nothing in the corpus alleges anything about Brookfield's marks. But fee-related earnings are a function of fee-bearing capital, fee-bearing capital is a function of limited-partner appetite for private vehicles, and this lane describes that appetite tightening across the board. It is a headwind on the input, not an accusation about the output. That is exactly enough to argue for waiting and not enough to argue for avoiding.

4. Valuation — priced in or room?

At $50.69 (market cap $80.94B, EV $85.32B per the TTM key-metrics bridge, ~1.62B diluted shares):

Ignore the FY29E line. Consensus for 2029-12-31 shows revenue falling to $5.078B on five analysts with a single EPS estimate ($2.71483). A revenue line that drops 36% between FY28E and FY29E is a coverage artifact, not a forecast. It is excluded from every calculation here.

Synthos fair values — stated arithmetic, no DCF theater:

• Bear ~$43 = 20x FY27E consensus EPS of $2.16564 = $43.31. The de-rating case: the private-capital cycle bites, fundraising slows, incentive fees compress, and BAM trades like a cyclical rather than a compounder. Lands just above the 52-week low of $42.20-42.87. -15.2% from spot.
• Base ~$56 = 26x FY27E consensus EPS of $2.16564 = $56.31. The base multiple is set at 26x because that is roughly where a business compounding EPS ~18% a year at 30% ROE and 1.4x leverage should clear once the FY26 print de-risks the fundraising question — and because it brackets the street's own $57.21 consensus and $57 median. +11.1% from spot, plus the 3.71% yield.
• Bull ~$65 = 30x FY27E consensus EPS of $2.16564 = $64.97. Requires a full re-rating back toward a premium compounder multiple: the credit cycle proves benign, incentive fees inflect, and the AI-infrastructure capital cycle drives fee-bearing capital growth. Lands exactly on the street's high target of $65 and just above the 52-week high of $62.93. +28.2% from spot.

Cross-check on EV/EBITDA: the base $56 implies a market cap of ~$89.4B and, holding net debt at $2.07B, an EV of ~$91.5B — 17.5x FY27E consensus EBITDA of $5.227B, against 16.3x today. That is a modest expansion, consistent with the stated thesis, and not a heroic one.

6a. What today's price assumes (the inversion)

At $50.69 (23.4x FY27E consensus EPS), today's price embeds roughly the following falsifiable claims. Every figure below is consensus-derived arithmetic, labelled as such — not a Synthos forecast.

• Revenue compounds ~20% a year through FY28. Consensus revenue goes $4.608B (FY25 actual) → $6.113B (FY26E) → $7.096B (FY27E) → $7.983B (FY28E). That is a 20.1% CAGR over three years, versus the 15.8% actually delivered FY24→FY25. The price assumes the fundraising environment gets better, not worse, than the year just reported. Falsified by: any quarter where fee-bearing capital growth decelerates below the FY25 revenue rate.
• EPS reaches ~$2.54 by FY28 (consensus, three analysts) — a 67% increase on FY25's $1.52 in three years, with no meaningful share-count growth. Falsified by: further equity issuance, or FY26 EPS printing below the $1.83658 consensus.
• Net margin holds above 50%. TTM net margin is 52.3%; consensus FY27E net income of $3.516B on $7.096B of revenue implies 49.5%. The market is paying for margins to stay within ~3 points of an already-extraordinary level while the business scales 54%. Falsified by: compensation or fund-launch costs scaling faster than fee revenue — which is precisely what Q1'26's jump in operating expenses ($6M → $443M year-over-year) hints at.
• The market keeps paying ~23-26x forward. No de-rating, despite (i) an unresolved 116.6% payout ratio, (ii) a knowledge-base lane describing the private-capital cycle turning defensive, and (iii) a 20-analyst grade split that is genuinely divided (9 buy / 9 hold / 2 sell). This is the most fragile assumption in the price. In a cycle where alternative-manager multiples compress toward the low 20s or high teens, BAM's earnings can grow exactly as modelled and the stock can still fall to the $43 bear anchor.

6b. The return bridge (why the multiple moves)

Over the dive's 6-24 month horizon, the expected return decomposes as:

> expected return ≈ EPS growth + multiple drift + shareholder yield

• EPS growth: +17.9% (consensus FY26E $1.83658 → FY27E $2.16564). This is the only leg carrying real weight.
• Multiple drift: +2.6 turns, or roughly +11% — from the 23.4x the market pays on FY27E today to the 26x base assumption. This dive assumes modest multiple EXPANSION, and that is the fragile leg. The justification is risk normalisation, not growth acceleration: if the FY26 prints show fee-bearing capital still compounding while the credit cycle stays contained to direct lending, the discount BAM currently carries against its own quality metrics should partially close. If it does not, the return collapses to earnings growth alone.
• Shareholder yield: +3.71% (the $1.88 TTM distribution at $50.69). Buybacks add a further ~0.5% — FY25 saw $412M of repurchases against an $80.9B cap.

Say it plainly: most of the base-case return is earnings growth, and roughly a third of it needs the multiple to cooperate. Note also the mechanical trap the addendum warns about — 27.6x FY26E becoming 23.4x FY27E at a constant $50.69 is pure forward rolldown, not re-rating, and this dive does not count it as return.

6c. Variant perception (where we differ, what would surprise)

• Where we differ from the street: on timing, not on value. Consensus sits at $57.21 with a median of $57 — within 2% of this dive's $56 base. We have essentially no valuation edge here, and that is itself a verdict input. Per house rules, a no-edge name defaults toward Hold, and that is where this lands. The genuine divergence is not about the number; it is that the street's narrow $50-65 target band and 9-buy/9-hold/2-sell split describe a consensus that has already given up on the upside case — which is a poor setup for paying up before a print.
• Where we differ from the knowledge base's implied read: we think the private-credit lane is being over-applied to real-asset managers. The July-August 2026 claims are specific about direct lending, BDC marks, and insurer balance sheets (eurodollar_university 2026-08-01, conviction 68, naming ARCC and OWL; odd_lots 2026-07-31, conviction 65, on insurer overvaluation). Brookfield's franchise is infrastructure-, renewables- and real-estate-weighted. We expect BAM to prove less credit-cycle-sensitive than the BDCs the corpus is actually indicting — but we want a print to demonstrate it before paying for it.
• Positive surprise that would force a reprice up: the 2026-08-05 print showing fee-bearing capital growth accelerating and management commentary that fundraising conditions are stable, plus any narrowing of the payout-versus-operating-cash-flow gap. That combination would validate 26-30x and put the $65 bull anchor in play. Watchable event: the 2026-08-05 release and the fee-bearing capital disclosure inside it.
• Negative surprise that would force a reprice down: an incentive-fee air pocket (the $560M lumpy line), an inflow deceleration, or explicit management caution on limited-partner appetite. In that case the 20x FY27E bear anchor at $43 — which sits right on the 52-week low — becomes the operative level. Watchable number: quarterly Management Service fee growth versus the FY25 run-rate of $3.384B.

5. The payout question — the single most fragile item on the page

This deserves its own section because it is the one thing in the dataset that could not be explained away.

The TTM ratios agree: dividend payout ratio 116.6%, free cash flow per share $1.4410 against a distribution of $1.88 per share, and a dividendPaidAndCapexCoverageRatio of 0.79x.

Three readings are possible and the dataset does not adjudicate between them.

1. Accounting artifact of the restructuring. BAM Ltd.'s reported operating cash flow may capture only its proportionate share of the manager's cash generation while the dividend line reflects the full distribution — precisely the kind of mismatch a 2024-25 reorganisation that quadrupled the share count and total assets would produce. The FY25 balance sheet gained $12.8B of assets and the entity took on $2.5B of net new debt in the same year.

2. Genuine top-up. The manager may simply be distributing more than the listed entity's own cash generation, funded from the balance sheet and new debt — sustainable while net debt is only 1.39x EBITDA, but not indefinitely.

3. Timing. Distributions declared and paid on a calendar that does not align with the cash-flow statement's period.

What this dive does: flags it, does not resolve it, and prices it as a reason for caution rather than as a proven shortfall. It is the single most fragile assumption embedded in the price — because a 3.71% yield is a meaningful part of why the stock has a floor at all, and the reported cash-flow statement does not visibly fund it. The 2026-08-05 release is the natural place to check.

6. Balance sheet, capital allocation and technicals

Balance sheet (FY25, 2025-12-31): cash and equivalents $1.580B, total current assets $4.960B, total assets $17.213B, total current liabilities $1.180B, long-term debt $2.473B, total debt $3.653B, net debt $2.073B, total liabilities $6.921B, total equity $10.291B (of which $1.395B minority interest), goodwill $236M. Net-debt/EBITDA 1.39x, interest coverage 18.8x, current ratio 1.42x, debt-to-equity 0.71x. There is no solvency question anywhere in this story.

Capital allocation (FY25): $2.818B of distributions, $412M of repurchases, $58M of net acquisitions, $2.5B of net debt issued, ending cash up $1.179B. Read that sequence carefully — the company distributed more than it earned in operating cash flow and simultaneously raised $2.5B of debt. In a low-leverage entity that is a legitimate financing choice. It is also the reason §5 exists.

Insider activity: no signal. The eight most recent insider filings in this dataset are all from December 2023 and January 2024 — sales by BCP GP Ltd (described as a former 10% owner) at prices around $2.20-2.23, and one J-Other transfer by Brookfield REIT Adviser LLC. Prices of $2.20 against a $50.69 share price confirm these entries relate to a different security or a pre-reorganisation share class. There is no usable recent insider signal for BAM in this dataset, and none is claimed.

Technicals (2026-08-04):

• Price $50.69, +4.73% on the day, on 1.90M shares against a 2.84M average — a move on below-average volume, into tomorrow's print.
• -19.5% from the 52-week high ($62.93); +18.2% from the 52-week low ($42.87). Max drawdown from peak -19.8%.
• Above the 50-DMA ($47.10) by 7.6% and above the 200-DMA ($49.31) by 2.8%. Both reclaimed — the primary trend is no longer broken, but it is only just repaired.
• RSI 62.9 — firm, not overbought. MACD +0.52 — positive.
• Relative performance is the damning number: 12-month return -17.8% against SPY +19.9% and QQQ +23.9%. Three-month +5.6% against SPY +5.1% — i.e. the underperformance has stopped, but none of it has been recovered.

7. Moat and competitive position

The moat is real but narrower than the margins suggest. What Brookfield actually owns is a multi-decade operating track record in hard assets, a global origination footprint, and the scale to write cheques few competitors can — the FY25 geographic disclosure spans ten named regions across four continents. Limited partners re-up with managers who have deployed through cycles in infrastructure and renewables, and that relationship is genuinely sticky; the 85.8% recurring Management Service fee share is the evidence.

What it is not is a structurally protected franchise. Fee rates are competitively determined and have compressed across the industry for a decade. The named peer set in this dataset — APO (Apollo, $74.6B cap), KKR ($95.7B), BK, ICE, MCO, MMC, BMO, MFG, COIN, and BN (Brookfield Corporation, $97.2B, the parent) — competes for the same institutional dollar. This dataset does not contain forward estimates for those peers, so no peer multiple comparison is offered here; asserting one would require numbers we do not have. The honest statement is that BAM's 30% ROE and 52% net margin are top-decile among listed managers, and that this is why it deserves a premium multiple — not that it deserves an unassailable one.

The one genuine structural advantage worth naming: BAM's real-asset tilt is the least AI-disruptable corner of asset management. The knowledge base captures the idea directly, if not the ticker (compound_and_friends, 2026-03-24, conviction 55: "the 'Halo' trade — Blackstone, Bain, Brookfield pivoting to hard assets with low obsolescence… less likely to be made extinct by AI"). Toll roads and transmission lines do not get disintermediated by a model.

8. Verdict, kill-criteria and flip conditions

Hold. Brookfield Asset Management is a genuinely superior business — 52.3% net margin, 30.0% ROE, 53.1% ROIC, 1.39x net-debt/EBITDA, 85.8% recurring fee mix, and consensus EPS compounding ~18% a year on 9-10 analysts. At $50.69 it trades at 23.4x FY27E against a stated-arithmetic base of 26x = $56, or +11.1% plus a 3.71% yield. That is a fair price for a fine business, not a bargain.

Four things stop this being a Buy, and they are cumulative rather than individually fatal:

1. Zero conviction. No tracked thinker names this ticker. The panel does not own it, has not underwritten it, and the only thing the corpus says about its neighbourhood is bearish. A name with no conviction lane does not get bought at a 10% discount to fair value — it gets bought at a 30% one.

2. The payout is unexplained. Distributions have exceeded reported operating cash flow for three consecutive years; the TTM GAAP payout ratio is 116.6%. Probably a restructuring artifact. Probably. §5 is the reason for the word "probably."

3. The cycle input is turning. The knowledge base's private-credit lane runs bearish at conviction 62-80 from 2026-07-04 through 2026-08-01. It does not indict Brookfield. It does describe the fundraising weather.

4. Earnings are tomorrow. 2026-08-05, consensus EPS $0.4321 on revenue $1.4657B. There is no reason to pay up for an 11% gap the day before a binary event.

How to act on a Hold:

• Already own it: hold. The 3.71% yield, the reclaimed 200-DMA, and an 11% gap to base fair value do not justify selling a 30%-ROE compounder. Do not add before the print.
• New money: wait for one of two triggers. (a) The 2026-08-05 print confirming fee-bearing capital growth with stable fundraising commentary — then build toward a 1-2% position on strength. (b) A pullback into the $43-47 zone (the 20x FY27E bear anchor through the 50-DMA), which would offer a 20%+ gap to base and a genuine margin of safety.
• Sizing discipline: 1-2% maximum regardless of how good the print is. The absence of any conviction lane is the binding constraint, not the fundamentals.

Pre-registered KILL / avoid-adding criteria:

• Fee-bearing capital growth turns negative, or Management Service fee revenue decelerates below the FY25 run-rate ($3.384B annualised) — the core annuity cracking.
• The payout gap widens rather than narrowing, or the distribution is funded by a further step-up in net debt issuance beyond FY25's $2.5B.
• The private-credit stress migrates into real assets — specifically, any tracked claim naming Brookfield's marks, redemptions, or gating, which would convert an adjacent headwind into a direct one.
• FY27E consensus EPS drifts below ~$2.00 (from $2.16564), which would move the 26x base fair value below $52 and remove the upside case entirely.
• The 200-DMA (~$49.31) is decisively lost after having just been reclaimed — a failed reclaim is a worse technical signal than never having reclaimed at all.

Pre-registered FLIP TO BUY:

• The 2026-08-05 print beats on fee-bearing capital and management addresses the distribution coverage explicitly and the price is still under ~$52 — that is a 26x base with the main uncertainty resolved.
• Or the price reaches $43-47 without any deterioration in the FY27E consensus EPS of $2.16564 — a 20-30% gap to base, which is the discount a zero-conviction name needs to earn a position.
• Or a tracked thinker initiates direct coverage of BAM with meaningful conviction, which would change the sizing constraint rather than the valuation.

Where BAM fits in the Synthos Framework Portfolio. The financials / real-asset-manager sleeve, as a 1-2% satellite position at most, and only for new money after the print. It is deliberately not a core holding: the quality argues for one, but the total absence of conviction coverage and the unresolved payout question argue against it, and when those two disagree, size down. On overlap: BAM is the fee expression of real assets, while a name like MPLX or ET (elsewhere in this batch) is the asset expression — BAM earns a percentage of other people's infrastructure, the midstream partnerships own theirs. They are complementary, and BAM's 3.71% yield is the lowest of the three, so it is not the income leg of the sleeve. Logged as a tracked Synthos call (Hold) as of 2026-08-04 at $50.69.

Single biggest risk: the private-capital fundraising cycle. Everything about BAM's economics — the 52% net margin, the 30% ROE, the 18% consensus growth path — is downstream of institutions continuing to allocate to private vehicles. The knowledge base's own most active recent lane says that allocation is turning defensive. BAM can execute perfectly and still see fee-bearing capital growth stall, at which point a 23.4x multiple on a 30%-ROE compounder becomes a 17x multiple on a low-growth annuity, and the $43 bear case arrives without anything "going wrong" at the company.

Single most fragile assumption in the price: that the market keeps paying 23-26x forward earnings while a 116.6% payout ratio goes unexplained and the private-capital cycle tightens. The earnings can come through exactly as consensus models them and the multiple can still take the stock to $43.

Provenance and disclosures

• Traceability: kb_claim_count 0. No tagged knowledge-base claim names the BAM ticker. One claim names the parent BN (jacob_shapiro, 2026-01-09, bullish, conviction 65); four others mention the Brookfield franchise inside broader theses (compound_and_friends 2026-03-24 conv 55; dylan_patel 2025-08-18 conv 68; lyn_alden 2021-07-22 conv 70, naming the separate BIP entity; invest_like_the_best 2026-07-21 conv 68, naming CCJ). One Brookfield-tagged entry sits in the misattribution quarantine and is excluded. Adjacent private-credit lane cited from eurodollar_university (2026-07-04, 07-08, 07-21, 07-23, 07-25, 08-01), odd_lots (2026-07-31, 08-02) and all_in (2026-07-21); all quotes verbatim. The verdict here is fundamentals-and-quant-driven only — the STM and NVTS precedent.
• Data as-of: fundamentals 2026-03-31 (Q1'26; annual figures 2025-12-31) · estimates 2026-08-04 · prices 2026-08-04 (quote $50.69, 50-DMA $47.10, 200-DMA $49.31, 52-wk range $42.20-$64.10 per quote / $42.87-$62.93 per technicals) · KB claims swept 2026-08-04. All market data from the single pre-pulled FMP dataset for this ticker. Nothing was re-fetched, recalled from memory, or estimated.
• Data gaps and inconsistencies, stated explicitly: (1) FY25 named segments total $3.944B against $4.608B of reported revenue — a $664M unexplained gap. (2) The geographic disclosure totals $68.116B, ~15x income-statement revenue, and is therefore group-level rather than BAM-level; it is used only as a footprint map. (3) Diluted share count and total assets are discontinuous across the 2024-25 reorganisation (389M → 1,121M → 1,646M shares; $3.2B → $17.2B assets), so pre-2025 per-share history is not comparable and is not used. (4) FY29E consensus shows revenue falling to $5.078B on five analysts with a single EPS estimate — excluded as coverage noise. (5) The Q1'26 earnings-calendar EPS actual ($0.43) differs from the income-statement diluted EPS ($0.38), consistent with an adjusted versus GAAP measure; both are shown. (6) Insider records in this dataset are all from Dec-2023/Jan-2024 at ~$2.20 prices and are not usable as a current signal. (7) The reported quarterly interest-expense line is volatile ($159M in Q1'25, $0 in Q4'25, $46M in Q1'26) and is not used for any trend.
• Fair-value caveat: the $43 / $56 / $65 anchors are scenario multiples on consensus FY27E EPS of $2.16564 (20x / 26x / 30x), cross-checked against FY27E consensus EBITDA of $5.227B. They are labelled scenario arithmetic, not a discounted cash flow. The base case assumes fee-bearing capital keeps compounding and that the payout question resolves benignly.
• Timing caveat: this dive is written the day before the Q2'26 print (2026-08-05), deliberately. The result may move the picture materially — particularly on the two open questions (fee-bearing capital growth and distribution coverage). Both entry triggers are structured around it.
• Not investment advice. Independent research, educational and informational only, never personalized.
• Version: 2026-08-04-full.